AstraZeneca (AZN) officer Sharma Mani granted additional Ordinary Shares

Rhea-AI Filing Summary

AstraZeneca PLC officer Sharma Mani reported routine share awards under the company’s Share Incentive Plan. On April 7, 2026, Mani acquired 1 Ordinary Share at $196.03, and on May 6, 2026, acquired 1 Ordinary Share at $186.28, both as grants rather than open-market purchases.

After these awards, Mani directly held a total of 31,155.4659 Ordinary Shares. The award prices reflect conversions from GBP148.06 and GBP136.76 using Federal Reserve exchange rates published in April and May 2026.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Sharma Mani

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	1	$186.28	$186.28
Grant/Award	Ordinary Shares	1	$196.03	$196.03

Holdings After Transaction: Ordinary Shares — 31,155.466 shares (Direct, null)

Footnotes (1)

1. Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP148.06, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3240 on April 7, 2026 as published by the Board of Governors of the Federal Reserve System. Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP136.76, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3621 on May 1, 2026 as published by the Board of Governors of the Federal Reserve System.

Key Figures

Share award (April 7, 2026): 1 Ordinary Share at $196.03 Share award (May 6, 2026): 1 Ordinary Share at $186.28 Holdings after transactions: 31,155.4659 Ordinary Shares +2 more

5 metrics

Share award (April 7, 2026) 1 Ordinary Share at $196.03 Grant under Share Incentive Plan on April 7, 2026

Share award (May 6, 2026) 1 Ordinary Share at $186.28 Grant under Share Incentive Plan on May 6, 2026

Holdings after transactions 31,155.4659 Ordinary Shares Direct ownership following reported awards

GBP price April award GBP148.06 per share Converted using GBP1.0000 = $1.3240 on April 7, 2026

GBP price May award GBP136.76 per share Converted using GBP1.0000 = $1.3621 on May 1, 2026

Key Terms

Share Incentive Plan, Ordinary Shares, Grant, award, or other acquisition, conversion rate, +1 more

5 terms

Share Incentive Plan financial

"Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP148.06"

A share incentive plan is a company program that gives employees or directors the chance to receive or buy company shares, often after staying with the firm or meeting performance goals. It matters to investors because it’s like giving workers a slice of the company pie to boost performance and loyalty, but issuing those slices can reduce each existing owner’s portion and change metrics such as earnings per share and share count.

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

conversion rate financial

"converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3240"

Conversion rate is the proportion of items, people or contracts that take a desired action out of the total possible — for example the share of website visitors who make a purchase, or the number of convertible bonds that are exchanged for shares. Investors care because it measures how effectively a business or financial instrument turns opportunity into real outcomes, like sales or share issuance, which directly affects revenue, cash flow and ownership dilution.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sharma Mani

(Last) (First) (Middle)

C/O ASTRAZENECA PLC 1 FRANCIS

CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE CB2 0AA

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASTRAZENECA PLC [ AZN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	04/07/2026		A		1	A	$196.03(1)	31,154.4659	D
Ordinary Shares	05/06/2026		A		1	A	$186.28(2)	31,155.4659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP148.06, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3240 on April 7, 2026 as published by the Board of Governors of the Federal Reserve System.

2. Represents the acquisition of shares pursuant to the Issuer's Share Incentive Plan at a price of GBP136.76, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3621 on May 1, 2026 as published by the Board of Governors of the Federal Reserve System.

Remarks:

SVP, Group Controller and Head of Global Finance Services

	/s/ Mani Sharma	05/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did AstraZeneca (AZN) report for Sharma Mani?

AstraZeneca officer Sharma Mani reported two small share awards. On April 7, 2026 and May 6, 2026, Mani each time received 1 Ordinary Share as a grant under the Share Incentive Plan, rather than buying shares in the open market.

What prices were used for Sharma Mani’s AstraZeneca (AZN) share awards?

The April 7, 2026 award used a price of $196.03 per Ordinary Share, and the May 6, 2026 award used $186.28 per share. These dollar amounts reflect conversions from GBP148.06 and GBP136.76 using Federal Reserve exchange rates on specified dates.

How many AstraZeneca (AZN) shares does Sharma Mani hold after these transactions?

Following the reported awards, Sharma Mani directly holds 31,155.4659 AstraZeneca Ordinary Shares. This total includes the 1-share grants reported for April 7, 2026 and May 6, 2026 under the company’s Share Incentive Plan, as disclosed in the Form 4 filing.

Were Sharma Mani’s AstraZeneca (AZN) transactions open-market buys or compensation grants?

The transactions were compensation-related grants, not open-market purchases. The Form 4 identifies each as a “Grant, award, or other acquisition” of 1 Ordinary Share under AstraZeneca’s Share Incentive Plan, with no shares marked as open-market buys or sells.

Did the AstraZeneca (AZN) Form 4 show any share sales by Sharma Mani?

No, the Form 4 only reports acquisitions. The transaction summary shows two acquisition entries and zero sell, gift, tax-withholding, or derivative exercise transactions, indicating the filing reflects awards of shares rather than any sales or disposals.